ENSC
Income statement / Annual
Last year (2025), Ensysce Biosciences Inc's total revenue was $5.07 M,
a decrease of 2.75% from the previous year.
In 2025, Ensysce Biosciences Inc's net income was -$10.18 M.
See Ensysce Biosciences Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$5.07 M |
$5.21 M |
$2.23 M |
$2.52 M |
$3.53 M |
$3.93 M |
$1.76 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$7.22 M
|
$7.59 M
|
$19.84 M
|
$151.00
|
$201.00
|
$3.40 M
|
$1.56 M
|
$0.00
|
| Gross Profit |
$0.00
|
-$2.01 M
|
-$5.36 M
|
-$17.31 M
|
$3.53 M
|
$3.93 M
|
-$1.64 M
|
-$1.56 M
|
$0.00
|
| Gross Profit Ratio |
0
|
-0.39
|
-2.4
|
-6.86
|
1
|
1
|
-0.93
|
0
|
0
|
| Research and Development Expenses |
$10.38 T
|
$7.22 M
|
$7.59 M
|
$19.84 M
|
$4.69 M
|
$4.39 M
|
$3.40 M
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$4.93 T
|
$4.72 M
|
$5.36 M
|
$6.91 M
|
$0.00
|
$0.00
|
$6.93 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.93 T
|
$4.72 M
|
$5.36 M
|
$6.91 M
|
$18.71 M
|
$1.15 M
|
$6.93 M
|
$0.00
|
$146.70 K
|
| Other Expenses |
-$15.31 T
|
-$7.22 M
|
-$7.59 M
|
-$19.84 M
|
$0.00
|
$0.00
|
-$3.40 M
|
$0.00
|
$0.00
|
| Operating Expenses |
$10.24 M
|
$4.72 M
|
$5.36 M
|
$6.91 M
|
$23.40 M
|
$5.54 M
|
$6.93 M
|
-$600.00 K
|
$146.70 K
|
| Cost And Expenses |
$10.24 M
|
$11.94 M
|
$12.95 M
|
$26.75 M
|
$23.40 M
|
$5.54 M
|
$10.33 M
|
$959.24 K
|
$146.70 K
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$1.25 M
|
$3.22 M
|
$719.65 K
|
$4.25 M
|
$3.63 M
|
$0.00
|
| Interest Expense |
$18.77 K
|
$1.29 M
|
$353.95 K
|
$109.53 K
|
$1.30 M
|
$995.50 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$6.53 K
|
$4.00
|
-$3.00
|
$151.00
|
$151.00
|
$201.00
|
$201.00
|
$0.00
|
$0.00
|
| EBITDA |
-$10.15 M |
-$6.73 M |
-$10.72 M |
-$24.22 M |
-$25.93 M |
$834.82 K |
-$8.57 M |
$2.68 M |
-$27.56 K |
| EBITDA Ratio |
-2
|
-1.29
|
-4.8
|
-9.6
|
-7.34
|
0.21
|
-4.86
|
0
|
0
|
| Operating Income Ratio |
-2.02
|
-1.29
|
-4.8
|
-9.6
|
-5.63
|
-0.41
|
-4.86
|
0
|
0
|
| Total Other Income/Expenses Net |
$64.76 K
|
-$1.26 M
|
$91.91 K
|
$14.41 K
|
-$9.28 M
|
$1.45 M
|
-$1.53 M
|
$3.64 M
|
$119.14 K
|
| Income Before Tax |
-$10.18 M
|
-$7.99 M
|
-$10.63 M
|
-$24.21 M
|
-$29.15 M
|
-$160.88 K
|
-$10.10 M
|
$2.68 M
|
-$27.56 K
|
| Income Before Tax Ratio |
-2.01
|
-1.53
|
-4.76
|
-9.59
|
-8.25
|
-0.04
|
-5.73
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$553.92 K
|
$3.64 K
|
| Net Income |
-$10.18 M
|
-$7.99 M
|
-$10.61 M
|
-$24.17 M
|
-$29.08 M
|
$56.77 K
|
-$10.10 M
|
-$1.34 M
|
-$31.19 K
|
| Net Income Ratio |
-2.01
|
-1.53
|
-4.76
|
-9.58
|
-8.24
|
0.01
|
-5.73
|
0
|
0
|
| EPS |
-3.98 |
-4.57 |
-4.69 |
-139.44 |
-355.68 |
0.56 |
0.24 |
-0.22 |
-0.0052 |
| EPS Diluted |
-3.98 |
-4.57 |
-4.69 |
-139.44 |
-355.68 |
0.56 |
0.24 |
-0.22 |
-0.0052 |
| Weighted Average Shares Out |
$2.56 M
|
$1.75 M
|
$2.26 M
|
$179.93 K
|
$84.02 K
|
$4.46 M
|
$6.09 M
|
$6.01 M
|
$5.98 M
|
| Weighted Average Shares Out Diluted |
$25.57 M
|
$1.75 M
|
$2.26 M
|
$179.93 K
|
$84.02 K
|
$6.37 M
|
$6.09 M
|
$6.01 M
|
$5.98 M
|
| Link |
|
|
|
|
|
|
|
|
|
